跳至主要内容

Antibodies (mAbs, ADCs, BSAbs)

Our offerings for monoclonal antibodies (mAbs) and antibody-related products (bispecific antibodies [BsAbs] and antibody-drug conjugates [ADCs]) deliver unbiased, high-quality insights to drive your development forward. With a focus on analytics, we provide impartial data analysis and tailored solutions that address the unique challenges of these modalities at every stage of development.
Contact Us
Microscopic image of an antibody

Our antibody offerings

  • Custom analytical method development: Tailored methods to address unique challenges in mAbs, BsAbs and ADC characterization

  • Analytical characterization, including comprehensive structural, potency and stability testing, including drug-to-antibody ratio (DAR) determination, glycosylation profiling and impurity analysis

  • Process development

  • Formulation development

  • Regulatory compliance support

  • Quality assurance

  • Technology transfer

As you bring transformative therapies to market, we're here to support you with extensive capabilities in biologics. Overcome the unique challenges of mAbs, BsAbs and ADC development for efficient and effective drug development.

Resources

Info Sheet

Antibody drug-conjugates (ADCs): Analytical considerations for QC release, stability testing, characterization and comparability

View Info Sheet

Info Sheet

Why cell line screening is crucial for successful complement-dependent cytotoxicity (CDC) assay development

View Info Sheet

Article

A stability screening method for predicting colloidal stability: Diffusion interaction parameter thermal shift assay

Read Article

Article

Characterizing the effector functions of therapeutic antibodies

Read Article

Article

N-Glycan Characterization with LC-MS

Read Article